Critical — contraindicated
Combination is contraindicated. Hard stop in the prescribing flow. Requires explicit override with clinical justification.
Decision support. ChironAI surfaces drug-interaction context for the prescribing clinician. The clinician decides whether to write, modify, or hold the prescription. ChironAI does not make a regulatory clearance claim; see Disclosures.
ChironAI CDSPrescribing
Prescriptions with the full pharmacology context.
ChironAI does not treat drug interactions as a checkbox warning. Before anything is drafted, the Chiron copilot runs a drug_interactions() check against the working medication list — so each prescription arrives with the full medication context (indication, mechanism, contraindication, dose-adjustment guidance) and each interaction surfaces with the pharmacology mechanism, severity tier, and the canonical source that warrants the call. The copilot proposes; it asks for your approval before it acts.
ChironAI CDS
Safety screened before anything is drafted.
cds.chirongrid.ai
Four-tier severity
From contraindicated to informational.
Major — monitor closely
Significant interaction risk. Monitoring required. Recommendation surfaced inline with the prescription.
Moderate — caution
Caution. Surfaced as informational alert. Clinician can proceed but should consider alternatives or counsel the patient.
Minor — informational
Informational. Surfaced for awareness; rarely changes the prescription. Suppressible per clinician preference.
A drug interaction in the product
ChironAI™ CDSDrug interaction · prescribing flow
Must review before final
Decision-support output. Clinician review and attestation required before this content is signed into the chart.
drug_interactions()
new: TMP-SMX · against: warfarin, lisinopril, metformin
One major interaction returned; two cleared. Surfaced before the script is drafted.
Interaction
Warfarin
×Trimethoprim-sulfamethoxazole
Critical — contraindicated
Mechanism
TMP-SMX inhibits warfarin metabolism via CYP2C9, displaces warfarin from protein binding, and may potentiate hypoprothrombinemia. INR can rise within 3–5 days of initiation, with bleeding risk.
Recommendation
Avoid combination if alternative antibiotic available. If unavoidable, reduce warfarin dose by 25–50% and monitor INR within 3–5 days.
Source — RxNorm + canonical pharmacology references. Verified against the published Warfarin-Sulfa interaction profile.
Awaiting your approval
Draft — Chiron copilotPrescriber approvesWritten to chart
Step therapy + prior auth flags
Surfaced before the prescription is signed.
When a prescription would trigger a step-therapy requirement or prior auth under common payer formularies, ChironAI surfaces the flag inline — before the clinician signs the script and the patient learns about it at the pharmacy.
The flag includes the typical step-therapy alternative or the prior-auth criterion that the prescription would need to satisfy. The clinician can adjust the prescription, request the prior auth, or proceed with explicit acknowledgement.
A note to the reader